You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Robert with photograph

Anoro Ellipta has demonstrated superior lung function improvement (trough FEV1) vs. another LAMA/LABA1

This is a fictional patient for illustrative purposes.

Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.2

When your COPD patients struggle with breathlessness, your choice of LAMA/LABA maintenance therapy could make a difference.

Explore Anoro Ellipta’s data vs. tiotropium/olodaterol1

Anoro Ellipta vs. tiotropium/olodaterol1

In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation), Anoro Ellipta demonstrated a 1.4x superior lung function improvement vs. tiotropium/olodaterol1 (with an extra 52mL improvement in trough FEV1)1

Trough FEV1 at week 8 in adults with moderate COPD* (ITT population)1

Graph demonstrating a 52mL improvement in lung function Image demonstrating an 52mL improvement in lung function

*Post bronchodilator FEV1 ≤70% to ≥50% predicted, mMRC ≥2;1
ITT, intention to treat; LS, least squares; MCID (minimum clinically important difference) = 100mL

Adapted from Feldman et al. 20171

  • An 8-week, randomised, open-label, non-inferiority, two-period crossover study in symptomatic patients with moderate COPD not on maintenance therapy for ≥2 weeks prior to randomisation. Patients had CAT≥10, mMRC≥2 and post-bronchodilator FEV1 of ≥ 50 to ≤ 70% predicted normal. Primary endpoint: change from baseline in trough FEV1 at Week 8 (assessed for non-inferiority using a non-inferiority margin of -50mL; followed by superiority).1

    Anoro Ellipta was well tolerated, with a comparable safety profile to tiotropium/olodaterol1

In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥2 weeks prior to randomisation), Anoro Ellipta reduced rescue medication use by an extra 38% vs. tiotropium/olodaterol1 (difference: 0.25 puffs/day)1

Change in rescue medication use (Weeks 1-8, ITT population)1

Image demonstrating a 38% reduction in rescue medication use Inhaler icon

ITT, intention to treat; LS, least squares; 

Adapted from Feldman et al. 20171

  • An 8-week, randomised, open-label, non-inferiority, two-period crossover study in symptomatic patients with moderate COPD not on maintenance therapy for ≥2 weeks prior to randomisation. Patients had CAT≥10, mMRC≥2 and post-bronchodilator FEV1 of ≥ 50 to ≤ 70% predicted normal. Primary endpoint: change from baseline in trough FEV1 at Week 8 (assessed for non-inferiority using a non-inferiority margin of -50mL; followed by superiority).1

    Anoro Ellipta was well tolerated, with a comparable safety profile to tiotropium/olodaterol1

Get started with Anoro Ellipta

Order demo device

PATIENT RESOURCES

You might also be interested in…

Dosing & the Ellipta device

Learn about the easy-to-use Ellipta device

Molecules

Anoro Ellipta contains umeclidinium (a LAMA) and vilanterol (a LABA)

Head-to-head data vs. a LAMA

See data for Anoro Ellipta vs tiotropium HandiHaler (a LAMA)

References

  1. Feldman G.J et al. Adv Ther 2017; 34:2518–2533
  2. ANORO Ellipta SPC https://www.medicines.ie/medicines/anoro-ellipta-55-micrograms-22-micrograms-inhalation-powder-pre-dispensed-31288/spc Accessed: July 2024

Anoro ▼ Ellipta is generally well tolerated. Consistent with its antimuscarinic activity, Anoro should be used with caution in patients with urinary retention or with narrow-angle glaucoma.2

Cardiovascular effects, such as cardiac arrhythmias e.g. atrial fibrillation and tachycardia, may be seen after the administration of muscarinic receptor antagonists and sympathomimetics, including Anoro.2

Therefore, Anoro should be used with caution in patients with severe cardiovascular disease.2

Common adverse reactions include: headache, urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, cough, oropharyngeal pain, constipation, dry mouth.2

You are advised to read the full safety information in the Anoro Ellipta Summary of Product Characteristics before prescribing.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSKI group of companies.

Innoviva Logo

PM-IE-UCV-WCNT-240005 July 2024